Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Ligelizumab?
Ligelizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Food Allergy. According to Globaldata,...
Data Insights
Ligelizumab by Novartis for Food Allergy: Likelihood of Approval
Ligelizumab is under clinical development by Novartis and currently in Phase III for Food Allergy. According to GlobalData, Phase III...